Optimer Pharmaceuticals Reports Second Quarter 2009 Financi...( Shares used ...)

Date:8/5/2009

====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 33,083,447 27,891,870 31,816,553 27,880,772 ========== ========== ========== ========== Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2009 2008 ---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $26,217,128 $16,778,880 Short-term investments 24,935,778 22,547,515 Prepaid expenses and other current assets 810,556 744,670 ------- ------- Total current assets 51,963,462 40,071,065 Property and equipment, net 623,892 694,183 Long-term investments 882,000 1,032,000 Other assets 498,171 498,250 ------- ------- Total assets $53,967,525 $42,295,498 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $4,091,178 $3,767,831 Accrued expenses 4,099,069 4,045,660 --------- --------- Total current liabilities 8,190,247 7,813,491 Deferred r
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures